Stock Movers: Intel, Mission Produce, Tango (Podcast)

The tape is being pulled in two very different directions: a long-duration capex winner in INTC and a single-asset clinical readout in TNGX, while AVO is a classic margin reset. The important second-order effect is not just that Google is diversifying TPU sourcing, but that a credible hyperscaler validation can re-rate Intel’s foundry/advanced packaging optionality across the rest of the AI supply chain; if the relationship scales, the market may start assigning value to future customer wins rather than current earnings power. That said, this is still a 2028 revenue story, so the move is more about sentiment and multiple expansion than near-term EPS.

TNGX is the more asymmetric setup because the market is likely discounting a path from early efficacy signal to platform credibility, and pancreatic oncology has a long history of false positives. The key is durability: if responses hold on confirmatory scan and the combo advances quickly into a front-line trial, the stock can stay inflated for months; if not, the drawdown can be violent because biotech rallies on small n are usually mean-reverting. RVMD has a quieter but real read-through: any perceived validation of daraxonrasib as a backbone therapy improves partnering and combination optionality across the KRAS space.

AVO is the opposite trade: the fundamental issue is that price/margin leverage in commodities can swing faster than operating volume growth can offset it. Improving supply conditions help, but if avocado pricing normalizes slowly, the equity can remain under pressure for another 1-2 quarters because investors tend to underwrite peak-margin recovery lazily and then cut estimates sharply once visibility improves. The contrarian point is that the market may be over-penalizing a transitory agricultural margin trough relative to the more structural upside in TNGX/INTC, creating a useful pair structure.